Nektar Therapeutics Inc (NKTR)

19.65 +0.22  +1.13% NASDAQ Nov 15, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/28/2020 17:00 EST Misc Nektar Therapeutics Inc Fourth Quarter Earnings Conference Call in 2019
02/28/2020 Earnings Nektar Therapeutics Inc Fourth Quarter Earnings in 2019 Release
11/06/2019 17:00 EST Misc Nektar Therapeutics Inc Third Quarter Earnings Conference Call for 2019
11/06/2019 Earnings Nektar Therapeutics Inc Third Quarter Earnings for 2019 Release
08/08/2019 17:00 EDT Misc Nektar Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/08/2019 Earnings Nektar Therapeutics Inc Second Quarter Earnings in 2019 Release
06/12/2019 14:00 PDT Misc Nektar Therapeutics Inc Annual General Meeting in 2018
05/08/2019 17:00 EDT Misc Nektar Therapeutics Inc First Quarter Earnings Conference Call in 2019
05/08/2019 Earnings Nektar Therapeutics Inc First Quarter Earnings in 2019 Release
02/28/2019 17:00 EST Misc Nektar Therapeutics Inc Fourth Quarter Earnings Conference Call in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.nektar.com
  • Investor Relations URL: http://ir.nektar.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Feb. 28, 2020
  • Last Earnings Release: Nov. 06, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Top Fund Holders

Symbol Name Weighting
GOFFX Invesco Oppenheimer Global Opp R5 4.86%
XPH SPDR® S&P Pharmaceuticals ETF 4.23%
FBT First Trust NYSE Arca Biotech ETF 3.50%
PBE Invesco Dynamic Biotech & Genome ETF 3.03%
INSLX Invesco Oppenheimer Intl Sml-Mid Com R5 2.62%
F000011APT GUGG Enhanced Quality 16 Strategy 13 CA 2.28%
CNCR Loncar Cancer Immunotherapy ETF 2.25%
POAGX PRIMECAP Odyssey Aggressive Growth 2.07%
PILL Direxion Daily Phrmctcl&MdclBl3XShrsETF 1.87%
FPHAX Fidelity® Select Pharmaceuticals Port 1.04%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.